Literature DB >> 29406446

Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer.

Yue Wang1, Xiaolong Ma, Yuxiang Wang, Yan Liu, Congrong Liu.   

Abstract

The objective of this article is to compare the effectiveness of various estrogen receptor (ER) scoring systems for predicting prognosis in endometrial cancer (EC). We retrospectively analyzed 195 cases of primary EC with complete follow-up information. Three different methods-the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criterion, histochemistry score (H-score), and Allred scoring system-were used to assess the degree of staining, and comparisons were made to determine which method correlated best with clinical outcomes. The ASCO/CAP criterion, H-score (cutoff value, 51-300), and Allred (cutoff value, 4-8) scoring systems showed high concordance in the following aspects: the ER status was significantly associated with subtype (type I vs. type II EC), newly recommended histologic type (grade 1-2, type I vs. grade 3, type I+type II EC), progesterone receptor status, overall survival, and cancer-specific survival in EC patients. Considering International Federation of Gynecology and Obstetrics stage, lymphovascular space invasion, and lymph node metastasis, the ASCO/CAP criterion significantly exceeded the other 2 scoring systems. Furthermore, cases judged as ER positive by the ASCO/CAP criterion, but ER negative by the other 2 scoring systems, displayed similarly favorable outcomes to those cases that were consistently admitted as ER positive by all 3 scoring systems. The ASCO/CAP criterion was superior to both H-score and Allred score in terms of predictive and prognostic values. This easy, simple, and highly efficient criterion should be recommended for routine assessment of ER in EC patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29406446     DOI: 10.1097/PGP.0000000000000490

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  3 in total

Review 1.  Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.

Authors:  Gian Franco Zannoni; Emma Bragantini; Francesca Castiglione; Matteo Fassan; Giancarlo Troncone; Frediano Inzani; Anna Pesci; Angela Santoro; Filippo Fraggetta
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

2.  Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer.

Authors:  Jing Yu; Hong-Wen Yao; Ting-Ting Liu; Di Wang; Jian-Hong Shi; Guang-Wen Yuan; Sai Ma; Ling-Ying Wu
Journal:  J Pers Med       Date:  2022-05-31

3.  Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Yovanni Casablanca; Guisong Wang; Heather A Lankes; Chunqiao Tian; Nicholas W Bateman; Caela R Miller; Nicole P Chappell; Laura J Havrilesky; Amy Hooks Wallace; Nilsa C Ramirez; David S Miller; Julie Oliver; Dave Mitchell; Tracy Litzi; Brian E Blanton; William J Lowery; John I Risinger; Chad A Hamilton; Neil T Phippen; Thomas P Conrads; David Mutch; Katherine Moxley; Roger B Lee; Floor Backes; Michael J Birrer; Kathleen M Darcy; George Larry Maxwell
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.